Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kristie Callahan

Nurse Practitioner, Family Jackson, MS Nurse Practitioner

NPI 1093129231 CMS profile 10571874

971 Lakeland Dr, Suite 557, Jackson, MS 39216

Open in the dashboard

General payments

$11,797

681 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kristie Callahan of Jackson, MS is reported in the CMS Open Payments database as having received $11,797 across 681 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,444 122
2024 General $2,265 121
2023 General $2,328 131
2022 General $2,646 164
2021 General $2,113 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kristie Callahan
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Kristie Callahan were reported at $2,444. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Kristie Callahan Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,113 $124 $35–$379 $132
2022 $2,646 $141 $44–$430 $149
2023 $2,328 $154 $49–$476 $160
2024 $2,265 $165 $51–$504 $164
2025 $2,444 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $936 64 payments
  2. Novartis Pharmaceuticals Corporation $827 58 payments
  3. ACADIA Pharmaceuticals Inc $727 46 payments
  4. SK Life Science, Inc. $723 35 payments
  5. Pfizer Inc. $660 42 payments
  6. UCB, Inc. $561 31 payments
  7. Teva Pharmaceuticals USA, Inc. $477 27 payments
  8. Genzyme Corporation $402 21 payments
  9. Argenx US, Inc. $392 18 payments
  10. Genentech USA, Inc. $389 27 payments
  11. Other $5,703 312 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,719 678 payments
  2. Education $78 3 payments
Products named General payments · program years 2021–2025
  1. NUPLAZID $569 35 payments
  2. Briviact $460 26 payments
  3. KESIMPTA Neurology $412 25 payments
  4. NURTEC ODT Pain $399 27 payments
  5. VYVGART Hytrulo $362 16 payments
  6. AUBAGIO $358 19 payments
  7. RELYVRIO $347 17 payments
  8. ZAVZPRET $343 23 payments
  9. KESIMPTA Neuroscience $328 25 payments
  10. NURTEC ODT Primary Care $322 21 payments
  11. Other $8,555 503 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 82 drugs

Part D claims

4,765

Median for Nurse Practitioner: 389

Drug cost

$271,138

Median for Nurse Practitioner: $21,885

Branded share of claims

19.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 96 $72,382
Ubrelvy Ubrogepant Brand 24 $32,915
Nuedexta Dextromethorphan Hbr/Quinidine Brand 14 $20,309
Vimpat Lacosamide Brand 17 $15,707
Aimovig Autoinjector Erenumab-Aooe Brand 12 $13,747
Ajovy Autoinjector Fremanezumab-Vfrm Brand 17 $13,048
Emgality Pen Galcanezumab-Gnlm Brand 19 $12,609
Myrbetriq Mirabegron Brand 12 $5,420
Lacosamide Generic 22 $4,802
Levetiracetam Generic 180 $4,510

The 10 drugs with the highest cost, of 82 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$77,571

Of which drugs: $23

Medicare patients

827

Average age 73

Services billed

2,080

559 women, 268 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 31%
Depression 31%
Diabetes 29%
Osteoporosis 19%
Atrial fibrillation 16%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 14 15 $14

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 44 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUPLAZID
$160 — —
BOTOX
$147 — —
VYVGART Hytrulo
$137 — —
PURIFIED CORTROPHIN GEL
$135 — —
Epidiolex
$111 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 44 with Patron

Records

681 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record